Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B

Marstacimab reduced annualized bleeding rate by 35% and 92% compared to routine prophylaxis and on-demand treatment in patients with hemophilia A and B without inhibitors, respectively Consistent reduction in bleeding rates observed after an...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials